Cardiff Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
Cardiff Oncology, Inc. (CRDF) filed a Current Report on Form 8-K on May 14, 2026. The filing announces a business update and financial results for the first quarter ended March 31, 2026. The company is incorporated in Delaware and operates from San Diego, California.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not disclose specific material changes versus the prior comparable period. It serves as a notification that the company has issued a press release containing these results.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, contingencies, and unusual items are not detailed in the Form 8-K text itself. The filing directs investors to the press release (Exhibit 99.1) for the business update and financial results.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 14, 2026) for specific Q1 2026 financial figures.
- Verify the company's cash runway and burn rate given the lack of disclosed liquidity metrics in this summary.
- Confirm any updates to the clinical pipeline or commercial strategy mentioned in the referenced business update.
- Check for any new debt covenants or financing activities disclosed in the full press release.